| Autor: |
Wang L; Department of Microbiology and Center of Infectious Diseases, Peking University Health Science Center, Beijing 100191, China., Liu XE; Department of Microbiology and Center of Infectious Diseases, Peking University Health Science Center, Beijing 100191, China., Zhuang H; Department of Microbiology and Center of Infectious Diseases, Peking University Health Science Center, Beijing 100191, China. |
| Jazyk: |
čínština |
| Zdroj: |
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology [Zhonghua Gan Zang Bing Za Zhi] 2021 Jun 20; Vol. 29 (6), pp. 604-608. |
| DOI: |
10.3760/cma.j.cn501113-20200708-00382 |
| Abstrakt: |
Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide and it includes simple fatty liver disease (NAFL), nonalcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma-related NASH. The degree of hepatic necrotizing inflammation and fibrosis is closely related to the long-term prognosis of NAFLD patients. Therefore, early monitoring of disease progression and intervention are of great significance. Liver biopsy, as an invasive test, has always been the gold standard for the diagnosis of NAFLD; however, it is not easy to carry out widely in clinical practice. With the development of omics-related research technologies, the potential application value of omics biomarkers such as genomics, transcriptomics, proteomics, glycomics, metabolomics, and so on in the diagnosis of NAFLD has gradually emerged. This review mainly summarizes the research progress of omics biomarkers for NAFLD. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
